Can Fite Biopharma Ltd Total Liabilities
Can Fite Biopharma Ltd total liabilities. Based on the latest financial reports, Can Fite Biopharma Ltd (CANF) has total liabilities worth ILA3.92 Million ILA (≈ $10.51K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Can Fite Biopharma Ltd (CANF) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Can Fite Biopharma Ltd (2003–2025)
Total liabilities of Can Fite Biopharma Ltd from 2003 to 2025. This chart illustrates how Can Fite Biopharma Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore investment intensity of Can Fite Biopharma Ltd to see how much of total assets are deployed in long-term investments.
Can Fite Biopharma Ltd Competitors by Total Liabilities
The table below lists competitors of Can Fite Biopharma Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Paranovus Entertainment Technology Ltd.
NASDAQ:PAVS
|
USA | $3.86 Million |
|
International Lithium Corp
V:ILC
|
Canada | CA$306.66K |
|
Clara Resources Australia Ltd
AU:C7A
|
Australia | AU$903.05K |
|
Universal Biosensors Inc
AU:UBI
|
Australia | AU$7.86 Million |
|
Colabor Group Inc.
TO:GCL
|
Canada | CA$322.31 Million |
|
Timah Resources Ltd
AU:TML
|
Australia | AU$27.78 Million |
|
Kingsland Minerals Ltd
AU:KNG
|
Australia | AU$502.41K |
|
Ecofin Global Utilities and Infrastructure Trust plc
LSE:EGL
|
UK | GBX16.93 Million |
Liability Composition Analysis (2003–2025)
This chart breaks down Can Fite Biopharma Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Can Fite Biopharma Ltd.
Liquidity & Leverage Metrics
Can Fite Biopharma Ltd Total Liabilities Ratios Explained
Can Fite Biopharma Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.46 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.70 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Can Fite Biopharma Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Can Fite Biopharma Ltd (2003–2025)
The table below shows the annual total liabilities of Can Fite Biopharma Ltd from 2003 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ILA3.92 Million ≈ $10.52K |
+6.48% |
| 2024-12-31 | ILA3.68 Million ≈ $9.88K |
-1.66% |
| 2023-12-31 | ILA3.75 Million ≈ $10.04K |
-22.14% |
| 2022-12-31 | ILA4.81 Million ≈ $12.90K |
-18.05% |
| 2021-12-31 | ILA5.87 Million ≈ $15.74K |
+70.22% |
| 2020-12-31 | ILA3.45 Million ≈ $9.25K |
-39.83% |
| 2019-12-31 | ILA5.73 Million ≈ $15.37K |
+16.10% |
| 2018-12-31 | ILA4.94 Million ≈ $13.24K |
+3.32% |
| 2017-12-31 | ILA4.78 Million ≈ $12.81K |
-24.07% |
| 2016-12-31 | ILA6.29 Million ≈ $16.87K |
-12.06% |
| 2015-12-31 | ILA7.16 Million ≈ $19.19K |
+114.89% |
| 2014-12-31 | ILA3.33 Million ≈ $8.93K |
+52.99% |
| 2013-12-31 | ILA2.18 Million ≈ $5.84K |
-7.11% |
| 2012-12-31 | ILA2.34 Million ≈ $6.28K |
+45.41% |
| 2011-12-31 | ILA1.61 Million ≈ $4.32K |
-70.56% |
| 2010-12-31 | ILA5.47 Million ≈ $14.68K |
-17.25% |
| 2009-12-31 | ILA6.62 Million ≈ $17.73K |
-6.41% |
| 2008-12-31 | ILA7.07 Million ≈ $18.95K |
-30.92% |
| 2007-12-31 | ILA10.23 Million ≈ $27.43K |
+199.06% |
| 2006-12-31 | ILA3.42 Million ≈ $9.17K |
+171.94% |
| 2005-12-31 | ILA1.26 Million ≈ $3.37K |
-59.25% |
| 2004-12-31 | ILA3.09 Million ≈ $8.28K |
+380.84% |
| 2003-12-31 | ILA642.00K ≈ $1.72K |
-- |
About Can Fite Biopharma Ltd
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase … Read more